Publicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (32)

2024

  1. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

    Nature Communications, Vol. 15, Núm. 1

2023

  1. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer

    Clinical Cancer Research, Vol. 29, Núm. 17, pp. 3292-3300

  2. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

    Nature Communications, Vol. 14, Núm. 1

  3. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

    Gynecologic Oncology, Vol. 178, pp. 119-129

  4. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 2, pp. 212-221

  5. Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials

    Annals of Oncology, Vol. 34, Núm. 1, pp. 70-77

  6. Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study

    European Journal of Cancer, Vol. 190

2022

  1. Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447] (ESMO Open (2022) 7(2), (S2059702922000631), (10.1016/j.esmoop.2022.100447))

    ESMO Open

  2. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

    Therapeutic Advances in Medical Oncology, Vol. 14

  3. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors

    ESMO Open, Vol. 7, Núm. 2

2021

  1. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 779-789

2020

  1. Atypical patterns of response and progression in the era of immunotherapy combinations

    Future Oncology, Vol. 16, Núm. 23, pp. 1707-1713

  2. ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

    ESMO Open, Vol. 5, Núm. 3

  3. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

  4. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer

    Gynecologic Oncology, Vol. 159, Núm. 1, pp. 142-149

2019

  1. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    Annals of Oncology, Vol. 30, Núm. 7, pp. 1080-1087

  2. Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” (European Urology (2018) 73(3) (462–468), (S0302283817310151) (10.1016/j.eururo.2017.11.023))

    European Urology

  3. Effectiveness of dabrafenib in the treatment of patients with braf v600-mutated metastatic melanoma in a named patient program

    Melanoma Research, Vol. 29, Núm. 5, pp. 527-532

  4. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

  5. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402